Last reviewed · How we verify

TEZ — Competitive Intelligence Brief

TEZ (TEZ) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CFTR corrector. Area: Pulmonary/Genetic Disorders.

marketed CFTR corrector CFTR (cystic fibrosis transmembrane conductance regulator) Pulmonary/Genetic Disorders Small molecule Live · refreshed every 30 min

Target snapshot

TEZ (TEZ) — Vertex Pharmaceuticals Incorporated. TEZ (tezacaftor) is a CFTR corrector that helps misfolded cystic fibrosis transmembrane conductance regulator (CFTR) protein fold correctly and traffic to the cell surface.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
TEZ TARGET TEZ Vertex Pharmaceuticals Incorporated marketed CFTR corrector CFTR (cystic fibrosis transmembrane conductance regulator)
VX-809 VX-809 Vertex Pharmaceuticals Incorporated phase 3 CFTR corrector CFTR
VX-661/Ivacaftor VX-661/Ivacaftor Vertex Pharmaceuticals Incorporated phase 3 CFTR corrector CFTR
ARINA-1 ARINA-1 Renovion, Inc. phase 3 CFTR corrector CFTR

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CFTR corrector class)

  1. Vertex Pharmaceuticals Incorporated · 3 drugs in this class
  2. Chiesi Farmaceutici S.p.A. · 1 drug in this class
  3. Renovion, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TEZ — Competitive Intelligence Brief. https://druglandscape.com/ci/tez. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: